Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | alphaDC1 + NK-like CTLs |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NK-like CTLs | autologous NK-like CTLs|autologous aDC1-induced CTLs | NK-like CTLs (nCTLs) are autologous T-lymphocytes that are treated with autologous alpha-type-1 dendritic cells that have been exposed to patient-specific tumor antigens, which potentially results in natural killer-like activity and increased tumor cell lysis (NCI Drug Dictionary). | ||
alphaDC1 | alpha-type-1-polarized DC|Alpha-type-1 Polarized Dendritic Cells | alphaDC1 is a polarized DC1 vaccine comprising autologous dendritic cells that is matured by treating with chemokines, potentially resulting in enhanced cytokine production and anti-tumor immune response against tumor cells (PMID: 15342370). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03735589 | Phase Ib/II | alphaDC1 + NK-like CTLs | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |